Carboxyl-ester lipase (encoded by *CEL*, MIM114840) is mainly expressed in the acinar cells of the pancreas and the lactating mammary gland^[@R1],[@R3]^. The enzyme is activated by bile salts in the duodenum and participates in the hydrolysis and absorption of cholesterol and lipid-soluble vitamins^[@R1]^. The human *CEL* locus on chromosome 9q34.3 also includes *CELP,* a tandemly arranged *CEL* pseudogene. The main difference between the two genes is that *CELP* lacks exon 2-7 of *CEL* and harbors a stop codon in its second exon (i.e. exon 8′, [Fig. 1a](#F1){ref-type="fig"}), otherwise the two genomic sequences are highly similar^[@R4],[@R5]^.

The last of the eleven CEL exons contains a variable number of tandem repeat (VNTR) region, consisting of nearly identical 33-bp segments^[@R3],[@R4]^. The segment number fluctuates between 7 and 23, with 16 repeats being the most common in all populations studied so far^[@R6]-[@R10]^. We have previously reported that single-base deletions in the *CEL* VNTR cause maturity-onset diabetes of the young, type 8 (MODY8, MIM609812), an autosomal dominantly inherited pancreatic disease characterized by diabetes and exocrine dysfunction accompanied by morphological changes of the gland^[@R2],[@R11]^. Therefore, we surmised that the highly polymorphic *CEL* gene might be a candidate for influencing the risk of chronic pancreatitis (CP), a complex, longstanding and progressive inflammatory disease resulting in gradual replacement of the pancreatic parenchyma by fibrous tissue. The clinical picture includes abdominal pain as well as exocrine and endocrine pancreatic insufficiency manifesting as maldigestion and diabetes, respectively.

The constellation of a gene and a nearby homologous sequence is well known to enhance the probability of genomic rearrangements, and can sometimes lead to new fusion genes that have altered functional properties and are associated with disease^[@R12]^. Copy number variants (CNVs) of *CEL* have been noted, both by others and us^[@R9],[@R10],[@R13]^. Fine-mapping the *CEL* locus of a subject known to carry an extra copy of *CEL* exon 11 revealed the presence of a duplication hybrid allele ([Fig. 1b](#F1){ref-type="fig"}, top panel). This allele apparently resulted from non-allelic homologous recombination ([Fig. 1c](#F1){ref-type="fig"}), the crossover occurring within an identical region of 522 bp in introns 9 of *CEL* and *CELP* (positions 12780-13301 in *CEL* and 28549-29070 in *CELP*; GenBank accession AF072711.1). The part consisting of *CELP-CEL* fusion sequence was, however, unlikely to encode a functional protein by virtue of its structural similarity to *CELP* ([Fig. 1b](#F1){ref-type="fig"}, top panel).

In contrast, the reciprocal recombination product of the duplication hybrid allele, namely a deletion hybrid allele, would potentially encode a novel CEL-CELP fusion protein based upon its predicted gene structure ([Fig. 1b](#F1){ref-type="fig"}, lower panel; [Fig. 1c](#F1){ref-type="fig"}). We developed a long-range PCR assay for its detection ([Supplementary Fig. 1](#SM){ref-type="supplementary-material"}), and among 190 Norwegian blood donors we found one positive subject. Subsequent DNA sequencing revealed that the identified deletion hybrid allele (denoted *CEL-HYB*) was not exactly reciprocal to the aforementioned duplication allele; the crossover occurred instead in a 548-bp identical region covering intron 10 and the adjacent exon boundaries ([Supplementary Fig. 2a](#SM){ref-type="supplementary-material"}). This might indicate that different recombination events have taken place in the intron 9-exon 11 region of the *CEL-CELP* locus.

We decided to investigate the role of *CEL-HYB* in the genetic etiology of CP. *S*creening a discovery cohort of 71 German subjects with familial CP ([Table 1](#T1){ref-type="table"}) revealed a carrier frequency of 14.1% (10/71) compared with 1.0% (5/478) in controls (odds ratio \[OR\] = 15.5; 95% confidence interval \[CI\] = 5.1-46.9; *P* = 1.3 × 10^−6^). To replicate this finding, we screened three independent cohorts (two German, one French) of non-alcoholic CP cases, as well as controls from each contributing laboratory. In each cohort, *CEL-HYB* was significantly overrepresented among CP cases ([Table 1](#T1){ref-type="table"}). For the three replication cohorts combined, *CEL-HYB* was present in 3.7% (42/1,122) of patients and 0.7% (30/4,152) of controls. Formal meta-analysis of the replication cohorts was highly significant (OR = 5.2, 95% CI = 3.2-8.5, *P* = 1.2 × 10^−11^). Among the 1,122 cases there were 57 individuals carrying rare *PRSS1* variants known to associate with hereditary CP. All *PRSS1* carriers tested negative for *CEL-HYB*. If these carriers were excluded from the study, the combined *CEL-HYB* frequency for cases increased to 3.9%. Upon meta-analysis of the three replication cohorts the OR was now 5.5 (95% CI = 3.4-8.9, *P* = 2.6 × 10^−12^).

We also examined the frequency of *CEL-HYB* in individuals with alcohol-related CP. Again, we found a significant enrichment of the *CEL-HYB* variant with a carrier frequency of 1.8% in cases versus 0.8% in controls (OR = 2.3, 95% CI = 1.2-4.4, *P* = 0.016) ([Table 1](#T1){ref-type="table"}). All *CEL-HYB*-positive individuals detected in the five cohorts studied were heterozygous carriers of the allele, except one homozygous case among the French patients (non-alcoholic CP cohort 3).

In the discovery cohort, family members from two of the *CEL-HYB* positive subjects were available for screening. Their pedigrees showed an autosomal dominant inheritance pattern of *CEL-HYB* although the allele did not fully co-segregate with pancreatitis ([Supplementary Fig. 3](#SM){ref-type="supplementary-material"}). Furthermore, when analyzing the *CEL-HYB* variant in 228 parents of patients from the German CP cohort 2, we detected six heterozygous parents. All of them had transmitted the risk allele to their affected child. Two parents had a diagnosis of pancreatitis. These observations confirm the high, but not absolute, risk associated with *CEL-HYB*.

To exclude the possibility that alterations in the exon 1-10 region of *CEL-HYB* could explain the disease association, we performed DNA sequencing of twelve *CEL-HYB*-positive cases. No predicted amino acid changes were observed in exons 1-9. In one CP patient, however, a premature stop codon was observed in exon 10 of the *CEL-HYB* reading frame. The corresponding mRNA may not be translated because of nonsense-mediated RNA decay and, if translated, the protein will not include the VNTR. All initially positive cases and controls were then screened for this minor *CEL-HYB* variant (found altogether in one case and four controls; not included in the carrier frequencies of [Table 1](#T1){ref-type="table"}).

To test whether the *CEL-HYB* risk variant might be identifiable indirectly through linkage disequilibrium (LD) with surrounding SNPs, we performed a detailed examination of genome-wide association study (GWAS) data in a subset of 787 individuals with known *CEL-HYB* status (25 carriers, 762 non-carriers). Proxy SNP analysis within the *CEL-CELP* LD region did not identify variants in strong LD with *CEL-HYB*. However, some distant correlating variants were found peaking at about 255 kb upstream of the *CEL-CELP* locus ([Fig. 2](#F2){ref-type="fig"}). No other SNPs correlating with the *CEL-HYB* variant at R^2^ ≥ 0.2 were identified on chromosome 9 outside the region shown in [Fig. 2](#F2){ref-type="fig"}. The best R^2^ was around 0.6 for a few imputed, highly correlated SNPs with low minor allele frequencies ([Supplementary Table 1](#SM){ref-type="supplementary-material"}). Moreover, to evaluate the origin of *CEL-HYB* we sequenced the exon 10-11 breakpoint region of 74 carriers of the allele. We observed five *CEL-HYB*-associated haplotypes ([Supplementary Fig. 2b](#SM){ref-type="supplementary-material"}), indicating that the variant has arisen by multiple independent recombination events. Thus, it is unlikely that a standard GWAS will be able to thoroughly tag and assess the *CEL-HYB* risk variant.

We also asked whether SNPs or rare variants within or adjacent to *CEL* exons 1-10 could be associated with CP outside the context of the *CEL-HYB* allele. Sequencing of 364 non-alcoholic CP cases and 238 controls revealed no variants that were overrepresented in the CP cohort ([Supplementary Table 2](#SM){ref-type="supplementary-material"}).

The *CEL-HYB* allele was predicted to encode a chimeric CEL protein of 589 amino acids, containing a functional enzyme region that derived from *CEL* but with a shorter and different VNTR originating from the *CEL* pseudogene ([Fig. 3a, b](#F3){ref-type="fig"}; [Supplementary Fig. 4a](#SM){ref-type="supplementary-material"}). To examine the functional consequences of *CEL-HYB*, we stably expressed the variant in human embryonic kidney (HEK) 293 cells, which do not have a detectable level of endogenous *CEL* mRNA or protein expression^[@R14],[@R15]^. We found that secretion of the CEL-HYB protein was reduced relative to the wild-type protein (CEL-WT) ([Fig. 3c](#F3){ref-type="fig"}). A similar result was observed in transiently transfected mouse acinar (266-6) cells ([Supplementary Fig. 4b](#SM){ref-type="supplementary-material"}).

Next, we investigated whether *CEL-HYB* might encode an overactive lipase. Carboxyl-ester lipase activity was measured using conditioned media from the CEL-expressing HEK293 cells, normalizing specific activity to the amount of CEL in the growth medium. When stimulated by bile salts, the CEL-HYB enzyme reached only about 40% of CEL-WT activity ([Fig. 3d](#F3){ref-type="fig"}). An artificial, truncated variant of CEL (CEL-TRUNC) that was missing the whole VNTR, showed about 90% of WT enzyme activity, a finding also reported by others^[@R16],[@R17]^. We therefore propose that the impaired activity of CEL-HYB may relate to effects of the new protein C-terminus rather than to the lack of a normal VNTR. Further, our results strongly suggest that increased lipase activity is not involved in the disease mechanism.

Finally, we explored the intracellular fate of the protein. When protein synthesis was inhibited by cycloheximide, CEL-HYB accumulated in the cells to a much higher degree than CEL-WT ([Fig. 4a,b](#F4){ref-type="fig"}). This intracellular retention of CEL-HYB as well as its impaired secretion ([Fig. 3c](#F3){ref-type="fig"}) could indicate that the pathological effect involves injury inside the cell. We hypothesized that intracellular CEL-HYB might induce compensatory autophagy for removal of defective and excessive secretory proteins. Both when grown in rich and starvation medium there was a significant increase of the autophagy marker LC3-II in CEL-HYB-expressing cells ([Fig. 4c](#F4){ref-type="fig"}). Notably, there are reports on increased levels of LC3-II and impaired autophagic flux in pancreatitis, and it has been proposed that autophagic dysfunction might be a key initiating event in this condition^[@R18]^.

Almost all CP genes identified so far encode proteins of the protease/antiprotease system of the pancreatic acinar cells, such as cationic trypsinogen (*PRSS1*, MIM276000)^[@R19],[@R20]^, serine protease inhibitor Kazal type 1 (*SPINK1,* MIM167790)^[@R21]^, chymotrypsinogen C (*CTRC*, MIM601405)^[@R22],[@R23]^, carboxypeptidase A1 (*CPA1*, MIM114850)^[@R24]^, and anionic trypsinogen (*PRSS2*, MIM601564)^[@R25]^. Other genetic risk factors are *CFTR* (MIM602421)^[@R26],[@R27]^ and SNPs in the *CLND2*-*MORC4*^[@R28],[@R29]^, *ABO* and *FUT2* loci^[@R30]^. Here we have identified *CEL* as a new gene for CP. This is the first lipase gene to be directly associated with pancreatitis. Different from most genes listed above, our functional studies suggest a pathogenic mechanism that does not involve premature activation of pancreatic digestive enzymes to initiate CP.

The odds ratio (5.2) of *CEL-HYB* in the non-alcoholic CP cohorts is comparable with that of the *CTRC* gene^[@R22]^. However, disease-associated *CTRC* variants tend to occur together with heterozygous *PRSS1* or *SPINK* variants^[@R31],[@R32]^. This contrasts our findings for *CEL-HYB*: among the 67 positive cases of [Table 1](#T1){ref-type="table"} there were none with a *PRSS1* mutation and only one *SPINK1* p.N34S/*CEL-HYB* trans-heterozygous patient.

We also detected a significant enrichment for *CEL-HYB* in a cohort of alcohol-related CP (OR = 2.3). Alcohol abuse is the leading cause of CP, accounting for about 70% of the cases^[@R33]^. Only a minority of long-term alcohol abusers develops CP, suggesting the presence of genetic risk factors, but the role of such factors is less understood than in non-alcoholic CP. So far, it has been reported that *SPINK1* and *CTRC* variants as well as SNPs in the *PRSS1-PRSS2*, *CLDN2-MORC4, ABO* and *FUT2* loci are associated with alcoholic CP^[@R22],[@R28]-[@R30],[@R34]^, all with modest odds ratios. Our findings suggest that *CEL-HYB* might be included among the relatively few genes known to interact with alcohol consumption to amplify CP risk. The data must, however, be interpreted with caution as the role of alcohol may sometimes be overestimated in CP and therefore alcoholic CP materials would be expected to include also some cases of idiopathic disease.

Finally, we note that classical molecular genetic techniques (long-range PCR, cloning, Sanger DNA sequencing) were necessary to map and analyze the genomic rearrangements of the *CEL-CELP* locus. Our detailed SNP analysis of the *CEL-CELP* region ([Fig. 2](#F2){ref-type="fig"}) indicates that current high-throughput methodologies such as GWAS of common variants and exome sequencing would be unlikely to uncover *CEL-HYB* and its role in pancreatitis. When genetic risk loci involve complex and highly repetitive regions, these techniques have some inherent limitations, as recently illustrated by the failure of detecting mutations in the VNTR of *MUC1* by massively parallel sequencing^[@R35]^. The identification of *CEL-HYB* as a novel pancreatitis gene therefore nicely highlights that in-depth analysis of the more complex regions of our genome still can play an important role in elucidating the genetic etiology of human disorders.

URLs {#S1}
====

FinchTV, <http://www.geospiza.com/ftvdlinfo.html>; 1000 Genomes, <http://mathgen.stats.ox.ac.uk/impute/data_download_1000G_phase1_integrated.html>; Ensembl release 70, <http://Jan2013.archive.ensembl.org/biomart/martview/3e14905c6880c3043c1>.

METHODS {#S2}
=======

Methods and any associated references are available in the online version of the paper.

METHODS {#S3}
=======

Subjects {#S4}
--------

The medical ethical review committees of all participating study centers approved this study. For the discovery phase, we screened 71 unrelated German patients with a diagnosis of familial, non-alcoholic CP, recruited by the University of Greifswald. These patients had unknown genetic etiology as they had previously tested negative for well-established pancreatitis risk genes. For the replication studies, we investigated 1,122 unrelated non-alcoholic CP subjects from University of Leipzig (cohort 1; n=260), Technische Universität München (cohort 2; n=510), and University of Bretagne, Brest (cohort 3; n=352). All cases in the replication cohorts had been screened for rare *PRSS1* variants associated with hereditary CP as well as the *SPINK1* p.N34S risk variant. The three German patient cohorts were compared to exclude any duplicate samples. In addition, we investigated 853 unrelated German subjects with alcoholic CP from Greifswald (n=214), Leipzig (n=296) and Munich (n=343). Controls were healthy blood donors (Greifswald, n=478; Leipzig, n=569; Munich, n=2,362; Brest, n=1,221). Norwegian blood donors (n=190) were used for the initial identification of *CEL-HYB*.

The diagnosis of CP was based on the presence of a typical history of recurrent pancreatitis (≥ 2 acute pancreatitis attacks) and/or other typical findings upon imaging like pancreatic calcifications. Familial CP (discovery cohort) was diagnosed when two or more family members in more than one generation suffered from pancreatitis. The patients of the replication cohorts were classified as having non-alcoholic CP when common risk factors such as alcohol abuse or other predisposing disorders were absent. Patients who reported a history of regular alcohol consumption of at least 60 g per day (women) or 80 g per day (men) were included in the alcoholic CP cohort.

Reference sequences {#S5}
-------------------

The following reference sequences have been used for primer design, sequence verification and SNP analysis of the *CEL-CELP* locus: GenBank accession number AF072711.1 (Homo sapiens carboxyl ester lipase gene, complete cds; and carboxyl ester lipase pseudogene, complete sequence); Ensembl database accession numbers OTTHUMG00000020855 (*CEL*) and OTTHUMG00000020857 (*CELP*).

Characterization of the *CEL* duplication hybrid allele {#S6}
-------------------------------------------------------

The presence of a *CEL* duplication was originally inferred by the DNA fragment analysis method of Torsvik et al., 2010^[@R9]^. Its allelic structure was worked out by PCR walking, using *LA Taq* polymerase (TaKaRa Bio) as described by the manufacturer. For mapping of the *CEL-CELP* recombination site, PCR products were verified by agarose gel electrophoresis, cloned into the pCR2.1-TOPO vector (Invitrogen), and analyzed by sequencing.

Screening for the *CEL* deletion hybrid allele {#S7}
----------------------------------------------

A long-range, duplex PCR assay was developed for the postulated deletion hybrid allele (*CEL-HYB)* as described in [Supplementary Fig. 1](#SM){ref-type="supplementary-material"}. We performed the reaction in a total volume of 10 μl, containing 1x GC buffer, 0.4 μM of each of the primers L11F, IAR and CELP-VNTR-R ([Supplementary Table 3](#SM){ref-type="supplementary-material"}), 1 M betaine solution, 0.4 mM of each dNTP, 0.5 U *LA Taq* polymerase, and 10-50 ng genomic DNA. Amplification started with a denaturation step at 94 °C for 1 min followed by 14 cycles of 94 °C for 20 sec and 60 °C for 6 min; then 16 cycles of 94 °C for 20 sec and 62 °C for 6 min, and a final elongation step of 72 °C for 10 min, followed by cooling to 4 °C. After visualization on a 1% agarose gel, all *CEL-HYB*-positive samples were finally verified by Sanger DNA sequencing.

For screening of *CEL-HYB* in larger materials, a high-capacity assay on the LightCycler 480 platform (Roche Diagnostics) was developed. We performed PCR using with forward and reverse primers as given in [Supplementary Table 3](#SM){ref-type="supplementary-material"} at a ratio of 5:1 (0.5 μmol/l and 0.1 μmol/l, respectively), 0.75 U OneTaq polymerase (New England BioLabs) and 0.4 mM of each dNTP, in a total volume of 25 μl. The cycle conditions were as follows: initial denaturation for 12 min at 95°C; 40 cycles of 20 s denaturation at 95°C, 40 s of annealing at 60 °C and 90 s of primer extension at 72 °C; and a final extension for 2 min at 72 °C. The amplified PCR products were then tested by melting curve analysis on the LightCycler 480. We used a SimpleProbe (TIB MOLBIOL) that allowed for discrimination between the *CEL* and *CELP* sequences by creating different melting points ([Supplementary Table 3](#SM){ref-type="supplementary-material"}). A representative image of screening results from the LightCycler assay is shown in [Supplementary Fig. 5](#SM){ref-type="supplementary-material"}.

Because the LightCycler assay was based on discrimination of SNPs in the breakpoint region some false positives were detected. All samples positive in the LightCycler assay were therefore subjected to the long-range PCR method above and sequenced for final verification. This approach was used when screening cases and controls recruited by the Leipzig and Munich groups. The other cohorts underwent primary screening directly by long-range PCR. The genotyping concordance for the long-range PCR assay was 100% for 533 duplicates tested.

Sanger DNA sequencing {#S8}
---------------------

Sequencing was performed by standard protocols on an ABI 3730 capillary sequencer (Applied Biosystems) using M13 forward or reverse primers, or *CEL*- and *CELP*-specific primers ([Supplementary Table 3](#SM){ref-type="supplementary-material"}).

When sequencing PCR products directly they were treated with ExoSAP (USB Corporation) as described by the manufacturer, and 2 μl of the treated PCR products were used as template. Sequencing results were analyzed by FinchTV (see URLs) or SeqScape (Applied Biosystems) software.

SNP mapping of the *CEL-CELP* region {#S9}
------------------------------------

Analysis of linkage disequilibrium between the *CEL-HYB* variant and SNPs on chromosome 9 was done in pancreatitis patients with available genetic data from Illumina Omni Human Express 700k SNP-chips. Genotypes of 2,824 patients were called with Illumina GenomeStudio. Quality control was done using PLINK. Thereby, the data were filtered for missingness per marker ≤ 0.05, missingness per individual ≤ 0.05, Hardy-Weinberg equilibrium p-value ≥ 10^−6^, cryptic relatedness filter PI_HAT ≤ 0.185, autosomal heterozygosity within 3 standard deviations, and population stratification to be not more extreme than ± 3 standard deviations. Following quality control, 2,712 individuals (2,065 male, 630 females, 17 of unknown sex) and 32,138 SNPs from chromosome 9 were used for imputation. Imputation was done using SHAPEIT v2 and IMPUTE 2.3.0, applying the 1000 Genomes reference phase 1, release 3 (see URLs). Blocks used in imputing were chosen to include the *CEL-CELP* locus ± 2 Mb in a single block. For post-imputation quality control, we filtered for SNPs with info-score smaller than 0.3.

For all further analyses, the cohort was limited to individuals with known *CEL-HYB* status, i.e. 787 individuals. Among these, 25 individuals (3.2 %) were carriers of the *CEL-HYB* allele. To identify proxies for *CEL-HYB*, we followed several strategies. First, we calculated Pearson's correlation of the *CEL-HYB* variant with allelic doses from imputed and directly measured genotypes ("gene dose" analysis). Additionally, we calculated haplotype-based R^2^ of directly typed SNPs and best-guess imputed genotypes. Here, we set all imputed genotypes with posterior probability smaller than 90% to missing. Confidence intervals of haplotype-based R^2^ were calculated as recommended^[@R36]^, applying jack-knife methodology to estimate standard errors. Aggressive two- and three-marker tagging was done using Tagger as implemented in Haploview 4.2 on measured and best-guess imputed genotypes.

*CEL-HYB* plasmid construction {#S10}
------------------------------

Human *CEL* wild-type (*CEL-WT*) cDNA was inserted into the pcDNA3.1/V5-His vector (Invitrogen). For the enzyme activity experiment, cDNA of a truncated variant of human *CEL* (*CEL-TRUNC)*, lacking the VNTR after nucleotide 1686, was inserted into the pcDNA3.1/V5-His vector. Both *CEL* variants were cloned in-frame with the V5-His tag of the pcDNA3.1/V5-His vector as described^[@R14],[@R15]^.

We used the *CEL-WT-V5/His* plasmid as template for creating the *CEL-HYB* construct. *Bam*HI and *Xho*I restriction sites flanked the VNTR sequence of the WT plasmid. A synthetic VNTR sequence of the *CEL-HYB* allele, flanked by the same restriction sites, was ordered (DNA 2.0). The VNTR of the template was then replaced by the *CEL-HYB* VNTR, creating a *CEL-HYB-V5/His* plasmid. The C substitution (rs77696629) observed in exon 10 of all *CEL-HYB*-positive subjects ([Supplementary Fig. 2a](#SM){ref-type="supplementary-material"}) was introduced by using the QuickChange II XL Site- directed Mutagenesis kit (Stratagene). The final structure of the *CEL-HYB* construct was confirmed by DNA sequencing. Before being employed in cellular experiments, the plasmid was tested *in vitro* by expression in the TNT T7 Quick-coupled Transcription/Translation System (Promega) ([Supplementary Fig. 4a](#SM){ref-type="supplementary-material"}).

Cell cultures and transfection {#S11}
------------------------------

HEK293 cells (Clontech) were cultured in *α*-minimal essential medium (Sigma) supplemented with 10% fetal bovine serum (Invitrogen), 4 mM L-glutamine (Sigma), and 1x Antibiotic-Antimycotic (Invitrogen). Hank's balanced salt solution (PAA - GE Healtcare) was used in starvation experiments. The 266-6 mouse pancreatic acinar cell line (ATCC) was grown in Dulbecco's Modified Eagle's Medium (ATCC) containing 10% fetal bovine serum (Invitrogen) and 1x Antibiotic-Antimycotic (Invitrogen). Both cell lines were maintained at 37°C in a 5% CO~2~-humidified atmosphere.

Transient transfection of *CEL-WT-V5/His*, *CEL-HYB-V5/His,* and the pcDNA3.1/V5-His empty vector in 266-6 cells was performed in 6-well plates using METAFECTENE PRO (Biontex) with a lipid (μl) to DNA (μg) ratio of 1:1. HEK293 cells stably transfected with *CEL-WT-V5/His*, *CEL-TRUNC-V5/His,* or the pcDNA3.1/V5-His vector were available in the lab^[@R14],[@R15]^. For stable transfection of the *CEL-HYB-V5/His* plasmid, HEK293 cells were transfected with the FuGENE 6 Transfection Reagent (Roche Diagnostics) with a 3:1 ratio of transfection reagent (μl) to DNA (μg). Cells were then grown under the selection of 500 μg/ml geneticin 418 (Invitrogen) for 18 days. Protein blotting and immunostaining confirmed expression of the CEL-HYB protein. All stable cell lines were maintained under constant geneticin selection.

Preparation of cell medium and lysate {#S12}
-------------------------------------

After transient transfection (48 h), 1 ml conditioned medium was isolated and centrifuged for 5 min at 13,000 rpm and 4°C. The supernatant was collected and analyzed. Total cell lysate was prepared by washing the cells in PBS before adding ice-cold Ripa buffer (Millipore) with 1x Complete Mini, EDTA-free protease inhibitor cocktail (Roche Diagnostics). The cells were added 150 μl Ripa buffer per well and incubated for 30 min at 4°C. The lysate was centrifuged for 15 min at 13,000 rpm and 4°C, and the supernatant was further analyzed as total cell lysate. Stably transfected cells were plated in 6-well plates (3 × 10^5^ cells per well) and grown for 48 h before isolation of cell medium and lysate, as described above. Quantification of total protein in cell lysates was measured using the BCA Protein Assay (Pierce).

Western blotting {#S13}
----------------

Lysates of 3 or 5 μg total protein were subjected to SDS-PAGE and Western blotting. For analysis of CEL protein secretion, the volume of medium loaded on the SDS gel was the same as for the corresponding lysate. The proteins were separated by 10% SDS-PAGE at 180 V for 1.5-2 hours and transferred to PVDF membranes by standard methods. The membranes were incubated with primary antibodies at 4°C overnight, washed, and incubated with secondary antibodies for 1 hour at room temperature. The blots were developed with the Enhanced Chemiluminiscence Plus Western Blotting Detection Kit (GE Healthcare) and further analyzed on a LAS-1000 imager (Fujifilm).

CEL activity assay {#S14}
------------------

Aliquots of conditioned media from stably transfected HEK293 cells expressing CEL-WT, CEL-TRUNC or CEL-HYB were used. HEK293 cells stably transfected with empty vector were included as negative control. The cells were grown to 80% confluency in normal growth medium. Subsequently, the medium was substituted with serum-free medium and the cells were incubated for additional 18 hours. Conditioned medium was collected and centrifuged at 300 × g and 4°C to remove detached cells, and kept on ice for immediate use.

CEL enzyme activity was measured using 4-nitrophenyl valerate (4-npv; Sigma) as substrate, monitoring the hydrolysis of 4-npv spectrophotometrically in the presence of sodium taurocholate (Sigma) as activator. The assay was performed at 37°C in a buffer containing 100 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 4-npv (solubilized in ethanol), and with sodium taurocholate concentrations varying between 0.02 and 20 mM. Reactions were run in triplicate in a 96-well microplate containing 115 μl buffer and 10 μl conditioned medium using an Infinite M200 Pro microplate reader (Tecan) with iControl Tecan Software, continuously monitoring the release of para nitrophenyl at 405 nm. The molar extinction coefficient of 4-npv was 11500 M^−1^cm^−1^. Enzyme activity was normalized against the amount of CEL in the conditioned media. CEL protein concentration was determined by SDS-PAGE and immunoblotting using titration of recombinant mouse CEL (5658-CE, R&D Systems) as a standard.

Treatments of stably transfected cells {#S15}
--------------------------------------

HEK293 cells were seeded in triplicate in 6-well plates (3 × 10^5^ cells per well), coated with poly-*L*-lysine (Sigma), and cultured for 48 hours before treatment. For investigating the rate of cellular CEL clearance during inhibition of protein synthesis, the cells were treated with 1 μg/ml cycloheximide (Sigma). Cell lysates were harvested for Western blot analysis after 0, 30, 60, and 90 min of treatment. For autophagy analysis, cells were incubated in full or starvation medium with or without Bafilomycin A1 (100 nM) for 3 hours, followed by harvesting of cell lysates for Western blotting.

Immunofluorescence and confocal microscopy {#S16}
------------------------------------------

Cells were seeded in 12-well plates (1.5 × 10^5^ cells per well), and grown on poly-*L*-lysine coated coverslips for 48 hours. Upon cycloheximide treatment, as described above, the cells were fixed for 30 min with 3% paraformaldehyde before they were immunostained as described previously^[@R37]^. After antibody staining, the coverslips were inverted onto objective glasses in a drop of ProLong Gold antifade mounting reagent (Molecular Probes) with DAPI (Invitrogen). The samples were examined using Leica TCS SP5 confocal microscope (Leica Microsystems) with a 63×/NA 1.4 Plan-Apochromat oil-immersion objective, \~1.2 Airy unit pinhole aperture, and the appropriate filter combinations. Images were acquired with Diode 405 and Argon lasers and processed using Adobe Photoshop CS5 image software (Adobe Systems). This experiment was repeated three times.

Antibodies {#S17}
----------

Protein expression in HEK293 and 266-6 cells was measured by Western blotting using the mouse anti-V5 primary antibody (R960-25, Invitrogen) or a rabbit polyclonal antibody (Vanko) for CEL detection. The Vanko antibody was raised against recombinant CEL lacking the VNTR-region and was a generous gift from Dr. Olle Hernell (Umeå University, Sweden). For detection of the autophagosome marker LC3, a rabbit polyclonal LC3B antibody (NB600-1384, Novus Biologicals) was employed. An antibody detecting beta-actin (sc-1615, Santa Cruz Biotechnology) was included to control for loading. Immunofluorescent staining of CEL was performed using the mouse monoclonal antibody As20.1, also kindly provided by Dr. Olle Hernell. AlexaFluor488-conjucated goat anti-mouse (A-11017, Invitrogen) was used as secondary antibody.

Statistical analyses {#S18}
--------------------

The significance of differences between allele frequencies in affected individuals and controls were tested by two-tailed Fisher's exact test, and OR and CI were calculated using Two-by-Two Table analysis in Stata/IC 13.0 (StataCorp). A fixed-effect model was used for the formal meta-analysis, which was performed by the method of Mantel and Haenszel, as implemented with the Metan version 9 module in Stata/IC 13.0, treating each study site as separate groups. For the functional protein analyses, significance of change was analyzed using a two-tailed, unpaired t-test. The difference was regarded significant when the *P*-value was ≤ 0.05. Results are given as mean ±SEM.
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![Copy number variants of the human *CEL* gene. The large red and blue boxes without numbers correspond to the complete *CEL* and *CELP* genes, respectively. Smaller boxes represent the individual exons and are numbered 1-11 (*CEL*) and 1′, 8′-11′ (*CELP*). The stop codon in exon 8′ of *CELP* is indicated. (**a**) Structure of the *CEL*-*CELP* gene locus. The grey-shaded area in *CEL* marks the exon 2-exon 7 region missing in *CELP*. The size of the locus is shown below the figure; exon and intron sizes are not drawn to scale. (**b**) Schematic structure of the duplication hybrid allele and the deletion hybrid allele (*CEL-HYB*) identified in this study. The breakpoint regions (not drawn to scale) are indicated by asterisks. (**c**) Proposed mechanism of the generation of *CEL-HYB* by non-allelic homologous recombination between *CEL* and *CELP*. The X symbolizes the cross-over event in the exon 10-exon 11 region.](emss-62314-f0001){#F1}

![Regional plot showing proxy SNPs of the *CEL-HYB* variant. R^2^ represents correlation between the *CEL-HYB* variant and SNPs based on measured and imputed gene doses. Recombination rate is according to 1,000 Genomes haplotypes Phase I (v3), and reported genes are from Ensembl release 70, January 2013 (see URLs). Genes were limited to biotypes 'protein-coding' and 'pseudogene'. Colors represent levels of R^2^ with *CEL-HYB*.](emss-62314-f0002){#F2}

![Altered structure, expression and enzyme activity of the CEL-HYB protein compared with wild-type CEL (CEL-WT). (**a**) Predicted structure of the two protein variants. The yellow box indicates the N-terminal signal peptide. The blue and green boxes correspond to the C-terminal VNTR region of the normal CEL protein and CEL-HYB, respectively. (**b**) Alignment of the amino acid sequence encoded by the first VNTR repeats of the *CEL-WT* and *CEL-HYB* alleles. The altered reading frame of *CEL-HYB* predicts a change of amino acid sequence starting in the first repeat and a premature stop-codon in repeat 3. Substituted amino acids are shown in red. **(c)** Expression of CEL-WT and CEL-HYB in stably transfected HEK293 cells. Cell lysates (L) and media (M) were analyzed by Western blotting. Transfection of empty vector (EV) was included as negative control. The actin bands indicate the amount of loaded protein in the lysate lanes only. The data are representative of more than three experiments giving similar result. **(d)** CEL enzyme activity in conditioned media from stably transfected HEK293 cells. Lipase activity was measured at 37°C in the presence of increasing concentrations of sodium taurocholate as activator. CEL-TRUNC, a variant of the CEL protein completely lacking the C-terminal VNTR, was included for evaluating the effect of the VNTR on enzyme activity. Data are shown as means of seven independent experiments, with statistical comparisons performed between CEL-HYB and CEL-WT activity. Error bars, SEM; \*, *P* = 0.01-0.05; \*\*, *P* = 0.001-0.01; \*\*\*, *P* \< 0.001.](emss-62314-f0003){#F3}

###### 

Intracellular properties of CEL-HYB. **(a)** Reduced cellular clearance of CEL-HYB. Stably transfected HEK293 cells were treated with the protein synthesis inhibitor cycloheximide (1 μg/ml) and examined at the indicated time points. Lysates from cells expressing CEL-WT or CEL-HYB were analyzed for CEL and actin by Western blotting (upper panel). The bands were quantified and CEL level normalized to actin (lower panel). CEL expression at time 0 was arbitrarily set to 1.0. After 120 min exposure to cycloheximide, 50% of CEL-HYB protein was detected in the cell lysate compared with 9% for CEL-WT. Data are shown as means of three independent experiments. Error bars, SEM; \*, *P* = 0.01-0.05. **(b)** Effect of cycloheximide confirmed by immunostaining and confocal imaging. Cells expressing CEL-HYB showed a much stronger fluorescence signal than CEL-WT-expressing cells after 120 min of cycloheximide treatment. Scale bar, 10 μm. **(c)** Autophagy induced by CEL-HYB expression. Stably transfected HEK293 cells were incubated in rich (fed) or starvation medium with or without bafilomycin A1 (BafA1) for 3 hours. Cell lysates were analyzed by Western blotting for CEL, actin and the autophagy marker protein LC3 (upper panel). The bands were quantified and LC3--II normalized to actin (lower panel). CEL-HYB-expressing cells grown in full or starved medium showed increased LC3-II levels as compared with CEL-WT-expressing cells. Data are shown as means of three independent experiments. Error bars, SEM; \*, *P* = 0.01-0.05.
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###### 

Heterozygous carrier frequencies of the *CEL-HYB* variant in German and French subjects with chronic pancreatitis

  Patient materials[\*](#TFN1){ref-type="table-fn"}              Cases    Controls                                             
  -------------------------------------------------------------- -------- ---------- --------- ----- --------- --------------- -------------------
  **Discovery cohort**                                           10/71    14.1       5/478     1.0   15.5      5.1 -- 46.9     1.3 × 10^-6^
                                                                                                                               
  **Non-alcoholic CP cohort 1**                                  11/260   4.2        5/569     0.9   5.0       1.7 -- 14.5     0.002
  **Non-alcoholic CP cohort 2**                                  22/510   4.3        16/2362   0.7   6.6       3.4 -- 12.7     1.3 × 10^−8^
  **Non-alcoholic CP cohort 3**                                  9/352    2.6        9/1221    0.7   3.5       1.4 -- 9.0      0.009
        **Meta-analysis** [\*\*\*](#TFN3){ref-type="table-fn"}   \-       \-         \-        \-    **5.2**   **3.2 - 8.5**   **1.2 × 10^−11^**
                                                                                                                               
  **Alcoholic CP cohort**                                        15/853   1.8        26/3409   0.8   2.3       1.2 -- 4.4      0.016

Cohorts are described in the Methods section

Two-tailed Fisher's exact test

Fixed effect model (in replication cohorts only). Z= 6.78; heterogeneity chi-squared = 1.18 (d.f. = 3), *P* = 0.553; I-squared
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